cisplatin, nivolumab
Nivolumab in combination with cisplatin and gemcitabine is approved by the USFDA for unresectable or metastatic urothelial carcinoma
March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment for adult patients with unres..
cisplatin, esophageal carcinoma, fluorouracil, GEJ, KEYNOTE-590, NCT03189719, Pembrolizumab
Pembrolizumab has been approved by the FDA for the treatment of esophageal or gastroesophageal junction cancer
August 2021: Pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy has been approved by the Food and Drug Administration for patients with metastatic or locall..